# A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital)

> **NCT05468307** · EARLY_PHASE1 · COMPLETED · sponsor: **Shanghai Juncell Therapeutics** · enrollment: 26 (actual)

## Conditions studied

- Advanced Gynecologic Tumors
- TIL Engineered With Membrane-Binding Cytokine
- Treatment Side Effects
- Effects of Immunotherapy

## Interventions

- **BIOLOGICAL:** Membrane Bound Cytokine Modified TIL

## Key facts

- **NCT ID:** NCT05468307
- **Lead sponsor:** Shanghai Juncell Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-10
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05468307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05468307, "A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05468307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*